Biocon Biologics UK
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Biocon Biologics UK sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Biocon Biologics UK: 2 sponsored US clinical trials, none currently recruiting.
Biocon Biologics UK sponsors 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Moderate-to-severe Chronic Plaque Psoriasis, with 1 trials.
Mid-pack sponsor footprint
Biocon Biologics UK is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT05335356
Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers: DENARIUS: DENosumab Pharmacokinetic equivAlence tRIal in Healthy volUnteerS
NCT05323708
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
Therapeutic Areas
How the Biocon Biologics UK archive is shaped
2 indexed studies, none listed as recruiting (0% open); 2 completed (100%).
Phase mix: 1 late (III/IV) vs 1 early (I/II) (balanced across stages).
Top condition: Moderate-to-severe Chronic Plaque Psoriasis (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Biocon Biologics UK: archived-pipeline peers nationwide
Peers matched on 2 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Biocon Biologics UK sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 archived trials
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Biocon Biologics UK page
2 registered trials is a research-attention snapshot, not an endorsement of Biocon Biologics UK or any single study.
- None of Biocon Biologics UK's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Moderate-to-severe Chronic Plaque Psoriasis is the condition Biocon Biologics UK studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Moderate-to-severe Chronic Plaque Psoriasis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Biocon Biologics UK pipeline card: 2 registered trials from official public datasets.Report a data error.